Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARO-ALK7
- Development stage
- Phase 2
- Lead developer
- Arrowhead Pharmaceuticals
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
ARO-ALK7 is an investigational small interfering RNA (siRNA) therapeutic developed by Arrowhead Pharmaceuticals for the treatment of obesity. It is designed to silence the expression of the ACVR1C gene in adipocytes, thereby reducing production of Activin receptor-like kinase 7 (ALK7), a receptor involved in regulating energy homeostasis and fat storage in adipose tissue. By inhibiting ALK7, ARO-ALK7 aims to reduce visceral adiposity and improve lipid and glycemic parameters. Preclinical studies have demonstrated significant reductions in body weight and fat mass with preservation of lean muscle. The drug is currently being evaluated as both a monotherapy and in combination with tirzepatide (a GLP-1/GIP receptor co-agonist) for enhanced effects on weight loss[1][2][3][5][6][8].
- Other names
- SGB-ALK7SGB-ALK-7SGB-ALK 7
02
Targets
ACVR1C (Activin A Receptor Type 1C)
Beyond the preview
Go deeper on ARO-ALK7.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARO-ALK7.